REGENERON PHARMACEUTICALS, INC. Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss
REGENERON PHARMACEUTICALS, INC. (REGN) had Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss of $14.58 million as of 2018-03-31, per its 10-Q filed 2018-05-03.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss · last filed 2018-05-03
- 2018-03-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss $14.58M.
- 2017-12-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss $5.34M.
- 2017-09-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss $2.71M.
- 2017-06-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss $9.51M.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss |
|---|---|
| 2018-03-31 | $14.58M 10-Q · filed 2018-05-03 |
| 2017-12-31 | $5.34M 10-Q · filed 2018-05-03 |
| 2017-09-30 | $2.71M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $9.51M 10-Q · filed 2017-08-03 |
| 2017-03-31 | $15.59M 10-Q · filed 2017-05-04 |
| 2016-12-31 | $18.93M 10-K · filed 2018-02-08 |
| 2016-09-30 | $13.92M 10-Q · filed 2016-11-04 |
| 2016-06-30 | $9.44M 10-Q · filed 2016-08-04 |
| 2016-03-31 | $5.84M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $2.68M 10-K · filed 2017-02-09 |
| 2015-09-30 | $1.06M 10-Q · filed 2015-11-04 |
| 2015-06-30 | $954.00K 10-Q · filed 2015-08-04 |
| 2015-03-31 | $88.00K 10-Q · filed 2015-05-07 |
| 2014-12-31 | $1.55M 10-K · filed 2016-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |